Across TCGA pan-cancer cohorts, GTF2IP1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GTF2IP1 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GTF2IP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GTF2IP1 expression acts as an unfavorable survival marker.
UCEC are the cancer types where GTF2IP1 Mutation most reproducibly stratifies survival.